nach oben

Journal of Cancer Research and Clinical Oncology

Erschienen in:

01.08.2014 | Original Article – Cancer Research

Aberrant expression of CD227 is correlated with tumor characteristics and invasiveness of breast carcinoma

verfasst von: Ya-Wen Wang, Duan-Bo Shi, Ya-Min Liu, Yan-Lin Sun, Xu Chen, Shuai Xiang, Qiang Fu, Jun-Min Wei, Peng Gao

Erschienen in: Journal of Cancer Research and Clinical Oncology | Ausgabe 8/2014

Einloggen, um Zugang zu erhalten

Abstract

Purpose

Increasing evidences demonstrate that CD227 plays a crucial role in the development and progression of breast cancer. However, the function of CD227 in breast carcinoma was still controversial and the investigation on CD227 in Asian race was scarce.

Methods

To investigate the relationship between CD227 and tumor characteristics of breast carcinoma, CD227, estrogen receptor (ER), progesterone receptor (PR), Her2⁄neu and Ki-67 were detected by immunohistochemistry in a series of 227 patients. The Kaplan–Meier method and log-rank tests were used to estimate the correlation between CD227 expression and patients’ prognosis. Furthermore, in vitro invasion assay was performed to examine the effect of CD227 on the invasiveness of breast carcinoma cells after transfection with CD227 cDNA or antisense phosphorothioate oligodeoxynucleotides (ASODN) against CD227 mRNA.

Results

Our data demonstrate that the cytoplasm staining and high expression of CD227 were positively related to the aggressiveness of breast cancer. Both circumferential membrane staining and cytoplasm staining were associated with lymph node metastasis. Moreover, the cytoplasm staining and overexpression of CD227 were found to be related to Her-2/neu positivity, higher Ki-67 positivity and poorer survival of patients. We further demonstrated that the invasion ability of breast carcinoma cells could be enhanced or inhibited by CD227 cDNA or ASODN, respectively.

Conclusions

We conclude that the aberrant expression of CD227, especially cytoplasm staining could be predictive for tumor aggressiveness, lymph node metastasis, poorer outcome of patients with breast cancers. And CD227 could promote the invasion ability of breast cancer cells, suggesting a potential role of CD227 as an oncogene in breast carcinoma.

Nur mit Berechtigung zugänglich

Acs G, Esposito NN, Rakosy Z, Laronga C, Zhang PJ (2010) Invasive ductal carcinomas of the breast showing partial reversed cell polarity are associated with lymphatic tumor spread and may represent part of a spectrum of invasive micropapillary carcinoma. Am J Surg Pathol 34(11):1637–1646. doi:10.1097/PAS.0b013e3181f5539c PubMed

Agrawal B, Krantz MJ, Parker J, Longenecker BM (1998) Expression of MUC1 mucin on activated human T cells: implications for a role of MUC1 in normal immune regulation. Cancer Res 58(18):4079–4081PubMed

Angus B, Napier J, Purvis J, Ellis IO, Hawkins RA, Carpenter F, Horne CH (1986) Survival in breast cancer related to tumour oestrogen receptor status and immunohistochemical staining for NCRC 11. J Pathol 149(4):301–306. doi:10.1002/path.1711490406 PubMedCrossRef

Arnerlov C, Ellis IO, Emdin SO (1988) Monoclonal antibody NCRC 11 reactivity with advanced breast carcinoma: lack of prognostic value. Histopathology 13(6):695–697PubMedCrossRef

Birner P, Oberhuber G, Stani J, Reithofer C, Samonigg H, Hausmaninger H, Kubista E, Kwasny W, Kandioler-Eckersberger D, Gnant M, Jakesz R, Austrian B, Colorectal Cancer Study G (2001) Evaluation of the United States Food and drug administration-approved scoring and test system of HER-2 protein expression in breast cancer. Clin Cancer Res 7(6):1669–1675PubMed

Borg A, Tandon AK, Sigurdsson H, Clark GM, Ferno M, Fuqua SA, Killander D, McGuire WL (1990) HER-2/neu amplification predicts poor survival in node-positive breast cancer. Cancer Res 50(14):4332–4337PubMed

Brugger W, Buhring HJ, Grunebach F, Vogel W, Kaul S, Muller R, Brummendorf TH, Ziegler BL, Rappold I, Brossart P, Scheding S, Kanz L (1999) Expression of MUC-1 epitopes on normal bone marrow: implications for the detection of micrometastatic tumor cells. J Clin Oncol 17(5):1535–1544PubMed

Carraway KL 3rd, Funes M, Workman HC, Sweeney C (2007) Contribution of membrane mucins to tumor progression through modulation of cellular growth signaling pathways. Curr Topics Develop Biol 78:1–22. doi:10.1016/S0070-2153(06)78001-2 CrossRef

Chomczynski P, Sacchi N (1987) Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem 162(1):156–159. doi:10.1006/abio.1987.9999 PubMedCrossRef

Cooke T, Reeves J, Lanigan A, Stanton P (2001) HER2 as a prognostic and predictive marker for breast cancer. Ann Oncol 12(Suppl 1):S23–S28PubMedCrossRef

de Roos MA, van der Vegt B, Peterse JL, Patriarca C, de Vries J, de Bock GH, Wesseling J (2007) The expression pattern of MUC1 (EMA) is related to tumour characteristics and clinical outcome in ‘pure’ ductal carcinoma in situ of the breast. Histopathology 51(2):227–238. doi:10.1111/j.1365-2559.2007.02754.x PubMedCrossRef

Dyomin VG, Palanisamy N, Lloyd KO, Dyomina K, Jhanwar SC, Houldsworth J, Chaganti RS (2000) MUC1 is activated in a B-cell lymphoma by the t(1;14)(q21;q32) translocation and is rearranged and amplified in B-cell lymphoma subsets. Blood 95(8):2666–2671PubMed

Fisher B, Redmond C, Fisher ER, Caplan R (1988) Relative worth of estrogen or progesterone receptor and pathologic characteristics of differentiation as indicators of prognosis in node negative breast cancer patients: findings from National Surgical Adjuvant Breast and Bowel Project Protocol B-06. J Clin Oncol 6(7):1076–1087PubMed

Gao P, Xing AY, Zhou GY, Zhang TG, Zhang JP, Gao C, Li H, Shi DB (2013) The molecular mechanism of microRNA-145 to suppress invasion-metastasis cascade in gastric cancer. Oncogene 32(4):491–501. doi:10.1038/onc.2012.61 PubMedCrossRef

Hayes DF, Mesa-Tejada R, Papsidero LD, Croghan GA, Korzun AH, Norton L, Wood W, Strauchen JA, Grimes M, Weiss RB et al (1991) Prediction of prognosis in primary breast cancer by detection of a high molecular weight mucin-like antigen using monoclonal antibodies DF3, F36/22, and CU18: a Cancer and Leukemia Group B study. J Clin Oncol 9(7):1113–1123PubMed

Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D (2011) Global cancer statistics. Cancer J Clinic 61(2):69–90. doi:10.3322/caac.20107 CrossRef

Kohlgraf KG, Gawron AJ, Higashi M, Meza JL, Burdick MD, Kitajima S, Kelly DL, Caffrey TC, Hollingsworth MA (2003) Contribution of the MUC1 tandem repeat and cytoplasmic tail to invasive and metastatic properties of a pancreatic cancer cell line. Cancer Res 63(16):5011–5020PubMed

Li YS, Kaneko M, Sakamoto DG, Takeshima Y, Inai K (2006) The reversed apical pattern of MUC1 expression is characteristics of invasive micropapillary carcinoma of the breast. Breast Cancer 13(1):58–63PubMedCrossRef

McGuckin MA (2001) CD227 (MUC1)—summary and workshop report. In: Mason D (ed) Leucocyte typing VII. Oxford University, Oxford, pp 54–56

McGuckin MA, Walsh MD, Hohn BG, Ward BG, Wright RG (1995) Prognostic significance of MUC1 epithelial mucin expression in breast cancer. Hum Pathol 26(4):432–439PubMedCrossRef

Nakamori S, Ota DM, Cleary KR, Shirotani K, Irimura T (1994) MUC1 mucin expression as a marker of progression and metastasis of human colorectal carcinoma. Gastroenterology 106(2):353–361PubMed

Nassar H, Pansare V, Zhang H, Che M, Sakr W, Ali-Fehmi R, Grignon D, Sarkar F, Cheng J, Adsay V (2004) Pathogenesis of invasive micropapillary carcinoma: role of MUC1 glycoprotein. Mod Pathol 17(9):1045–1050. doi:10.1038/modpathol.3800166 PubMedCrossRef

Parham DM, Slidders W, Robertson AJ (1988) Quantitation of human milk fat globule (HMFG1) expression in breast carcinoma and its association with survival. J Clin Pathol 41(8):875–879PubMedCentralPubMedCrossRef

Rahn JJ, Dabbagh L, Pasdar M, Hugh JC (2001) The importance of MUC1 cellular localization in patients with breast carcinoma: an immunohistologic study of 71 patients and review of the literature. Cancer 91(11):1973–1982PubMedCrossRef

Rakha EA, Boyce RW, Abd El-Rehim D, Kurien T, Green AR, Paish EC, Robertson JF, Ellis IO (2005) Expression of mucins (MUC1, MUC2, MUC3, MUC4, MUC5AC and MUC6) and their prognostic significance in human breast cancer. Mod Pathol 18(10):1295–1304. doi:10.1038/modpathol.3800445 PubMedCrossRef

Smith NL, Catrou PG, Payne G, Kellogg AE (2004) Patterns of expression of the DS6-glycoform of MUC1 correlates with known prognostic indicators in breast cancer. In: AACR Meeting Abstracts, 2004. p 239

Suwa T, Hinoda Y, Makiguchi Y, Takahashi T, Itoh F, Adachi M, Hareyama M, Imai K (1998) Increased invasiveness of MUC1 and cDNA-transfected human gastric cancer MKN74 cells. Int J Cancer 76(3):377–382PubMedCrossRef

Treon SP, Mollick JA, Urashima M, Teoh G, Chauhan D, Ogata A, Raje N, Hilgers JH, Nadler L, Belch AR, Pilarski LM, Anderson KC (1999) Muc-1 core protein is expressed on multiple myeloma cells and is induced by dexamethasone. Blood 93(4):1287–1298PubMed

van der Vegt B, de Roos MA, Peterse JL, Patriarca C, Hilkens J, de Bock GH, Wesseling J (2007) The expression pattern of MUC1 (EMA) is related to tumour characteristics and clinical outcome of invasive ductal breast carcinoma. Histopathology 51(3):322–335. doi:10.1111/j.1365-2559.2007.02757.x PubMedCrossRef

Wreesmann VB, Sieczka EM, Socci ND, Hezel M, Belbin TJ, Childs G, Patel SG, Patel KN, Tallini G, Prystowsky M, Shaha AR, Kraus D, Shah JP, Rao PH, Ghossein R, Singh B (2004) Genome-wide profiling of papillary thyroid cancer identifies MUC1 as an independent prognostic marker. Cancer Res 64(11):3780–3789. doi:10.1158/0008-5472.CAN-03-1460 PubMedCrossRef

Wykes M, MacDonald KP, Tran M, Quin RJ, Xing PX, Gendler SJ, Hart DN, McGuckin MA (2002) MUC1 epithelial mucin (CD227) is expressed by activated dendritic cells. J Leukocyte Biol 72(4):692–701PubMed

Yilmaz M, Christofori G (2010) Mechanisms of motility in metastasizing cells. Mol Cancer Res 8(5):629–642. doi:10.1158/1541-7786.MCR-10-0139 PubMedCrossRef

Yonezawa S, Goto M, Yamada N, Higashi M, Nomoto M (2008) Expression profiles of MUC1, MUC2, and MUC4 mucins in human neoplasms and their relationship with biological behavior. Proteomics 8(16):3329–3341. doi:10.1002/pmic.200800040 PubMedCrossRef

Yonezawa S, Higashi M, Yamada N, Yokoyama S, Kitamoto S, Kitajima S, Goto M (2011) Mucins in human neoplasms: clinical pathology, gene expression and diagnostic application. Pathol Int 61(12):697–716. doi:10.1111/j.1440-1827.2011.02734.x PubMedCrossRef

Titel: Aberrant expression of CD227 is correlated with tumor characteristics and invasiveness of breast carcinoma
verfasst von: Ya-Wen Wang
Duan-Bo Shi
Ya-Min Liu
Yan-Lin Sun
Xu Chen
Shuai Xiang
Qiang Fu
Jun-Min Wei
Peng Gao
Publikationsdatum: 01.08.2014
Verlag: Springer Berlin Heidelberg
Erschienen in: Journal of Cancer Research and Clinical Oncology / Ausgabe 8/2014
Print ISSN: 0171-5216
Elektronische ISSN: 1432-1335
DOI: https://doi.org/10.1007/s00432-014-1676-5

Klimawandel und Gesundheit: Was Sie in der Hausarztpraxis wissen müssen und tun können

Springer Medizin

Aberrant expression of CD227 is correlated with tumor characteristics and invasiveness of breast carcinoma